Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.35 USD

77.35
3,319,830

+0.48 (0.62%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $77.36 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (66 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises

by Zacks Equity Research

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag

by Zacks Equity Research

AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.

Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.

Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View

by Zacks Equity Research

Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.

AstraZeneca (AZN) Jumps: Stock Rises 5.7%

by Zacks Equity Research

AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment

by Kinjel Shah

AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.

AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up

by Zacks Equity Research

AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.

Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs

by Zacks Equity Research

Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.

Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA

by Zacks Equity Research

Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.

Mark Vickery headshot

Top Stock Reports for Cisco, Home Depot & Merck

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Home Depot (HD) and Merck (MRK).

AstraZeneca's Imfinzi Gains Orphan Drug Status for SCLC

by Zacks Equity Research

The FDA assigns an orphan drug designation to AstraZeneca's (AZN) Imfinzi for the treatment of small cell lung cancer, the most aggressive type of the ailment.

Intra-Cellular Therapies' Candidate Fails in Phase III Study

by Zacks Equity Research

Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

AVEO Pharmaceuticals Down More Than 50% YTD: Here's Why

by Zacks Equity Research

AVEO Pharmaceuticals (AVEO) suffers a major setback as it delays the NDA filing for Fotivda in the United States.

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Regulatory/Pipeline Updates, CHMP Nod for Several Drugs

by Kinjel Shah

Pfizer (PFE) provides several regulatory/pipeline updates. CHMP gives nod to several drugs.

Roche's Flu Medicine Xofluza Meets Goal in Study on Kids

by Zacks Equity Research

Roche's (RHHBY) new flu medicine, Xofluza is well tolerated in a study in children aged between one to 12 years. It is also comparable to Roche's older flu medicine, Tamiflu,

AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label

by Zacks Equity Research

AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.

AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study

by Zacks Equity Research

AstraZeneca (AZN) announces positive overall survival results from the phase III CASPIAN study evaluating Imfinzi in first-line extensive-stage SCLC.

Pfizer's Talzenna Gets Approval in Europe for Breast Cancer

by Zacks Equity Research

Pfizer's (PFE) PARP inhibitor, Talzenna, receives approval in Europe for treating BRCA-mutated locally advanced or metastatic breast cancer.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

by Kinjel Shah

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod

by Zacks Equity Research

AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.

Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

by Zacks Equity Research

Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

by Zacks Equity Research

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.